These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35662121)

  • 1. Platelet-Derived Amyloid-β Protein Precursor as a Biomarker of Alzheimer's Disease.
    Wang Q; Shi Y; Qi X; Qi L; Chen X; Shi J; Xie C; Zhang Z
    J Alzheimers Dis; 2022; 88(2):589-599. PubMed ID: 35662121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum.
    Lee J; Jang H; Kang SH; Kim J; Kim JS; Kim JP; Kim HJ; Seo SW; Na DL
    J Korean Med Sci; 2020 Nov; 35(44):e361. PubMed ID: 33200589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.
    Lim B; Tsolaki M; Soosaipillai A; Brown M; Zilakaki M; Tagaraki F; Fotiou D; Koutsouraki E; Grosi E; Prassas I; Diamandis EP
    Clin Chem Lab Med; 2019 Nov; 57(12):1875-1881. PubMed ID: 31415236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic Amyloid-β42 Conformer May Accelerate the Onset of Alzheimer's Disease in the Preclinical Stage.
    Futamura A; Hieda S; Mori Y; Kasuga K; Sugimoto A; Kasai H; Kuroda T; Yano S; Tsuji M; Ikeuchi T; Irie K; Ono K
    J Alzheimers Dis; 2021; 80(2):639-646. PubMed ID: 33579852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Cousins KAQ; Irwin DJ; Wolk DA; Lee EB; Shaw LMJ; Trojanowski JQ; Da Re F; Gibbons GS; Grossman M; Phillips JS
    Brain; 2020 Jul; 143(7):2295-2311. PubMed ID: 32666090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
    Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
    Hoscheidt SM; Starks EJ; Oh JM; Zetterberg H; Blennow K; Krause RA; Gleason CE; Puglielli L; Atwood CS; Carlsson CM; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016 Apr; 52(4):1373-83. PubMed ID: 27079723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
    Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
    Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease.
    Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R
    Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration.
    Mravinacová S; Alanko V; Bergström S; Bridel C; Pijnenburg Y; Hagman G; Kivipelto M; Teunissen C; Nilsson P; Matton A; Månberg A
    Mol Neurodegener; 2024 Feb; 19(1):15. PubMed ID: 38350954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.